NCT03548207 - A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

June 29, 2018

Primary Completion Date

August 23, 2022

Study Completion Date

August 23, 2022

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL

JNJ-68284528

JNJ-68284528 consist of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).

Trial Locations (21)

10029

Mount Sinai Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

15232

University of Pittsburgh Medical Center, Pittsburgh

19104

University of Pennsylvania, Philadelphia

28204

Levine Cancer Institute, Charlotte

37203

Sarah Cannon Research Institute, Nashville

48201

Barbara Ann Karmanos Cancer Institute, Detroit

53226

Froedtert Memorial, Milwaukee

55902

Mayo Clinic Rochester, Rochester

60637

University of Chicago, Chicago

68198

University of Nebraska Medical Center, Omaha

85054

Mayo Clinic Cancer Center-Scottsdale, Phoenix

91010

City of Hope, Duarte

94143

University of California San Francisco, San Francisco

02115

Dana Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Massachusetts General Hospital, Boston

602-8566

University Hospital Kyoto Prefectural University of Medicine, Kyoto

467 8602

Nagoya City University Hospital, Nagoya

060-8648

Hokkaido University Hospital, Sapporo

150-8935

Japanese Red Cross Medical Center, Shibuya City

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY